Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Lung Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Histamine H2 Antagonists × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03050866 2021-08-20

CABA-V7

Erasmus Medical Center

Phase 2 Unknown
140 enrolled
Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡